[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Muramaki M, Hara I, Miyake H, Yamada Y, Kawabata G, Kamidono S: Advances in the management of non-seminomatous germ cell tumors during the cisplatin era: a single-institution experience. Int J Urol; 2004 Sep;11(9):768-73
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in the management of non-seminomatous germ cell tumors during the cisplatin era: a single-institution experience.
  • BACKGROUND: The objectives of the present study were to review chronological changes in the long-term survival of patients with non-seminomatous germ cell tumor (NSGCT) who were treated at a single institution after the introduction of cisplatin-based combination chemotherapy.
  • To evaluate chronological changes in treatment outcome between 1978 and 2001, data were analyzed according to the timing of initial treatment in two consecutive 12-year periods.
  • Patients were classified according to criteria of both the Japanese Urological Association (JUA classification) and the International Germ Cell Cancer Collaborative Group (IGCCCG classification).
  • A significant improvement in survival was found in the patients with stage III disease, according to the JUA classification, and in the patients with poor-risk disease, according to the IGCCCG classification (P = 0.004 and 0.05, respectively).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Germinoma / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adult. Follow-Up Studies. Humans. Male. Neoplasm Staging. Retrospective Studies. Risk Factors. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15379942.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


2. El Sayed S, Grando JP, Almeida SH, Mortati Neto N, Moreira HA: Post-chemotherapy residual mass in non-seminomatous testicular cancer. The role of retroperitoneal lymph node dissection. Int Braz J Urol; 2004 Sep-Oct;30(5):384-8
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-chemotherapy residual mass in non-seminomatous testicular cancer. The role of retroperitoneal lymph node dissection.
  • PURPOSE: To determine the role of RPLND for residual masses following chemotherapy in patients with non-seminomatous germ cell tumors (NSGCT) stage T1N2 and T1N3 (IIB and IIC).
  • MATERIALS AND METHODS: We have preformed retrospective analysis of 11 patients who underwent RPLND for residual masses following chemotherapy in an oncologic reference center between January 1997 and December 2002.
  • All patients harbored either pure nonseminomatous or mixed tumors in the testis tissue and had undergone 4 cycles of primary chemotherapy with bleomycin, etoposide and cisplatin.
  • The residual masses were assessed by abdominal computed tomography preoperatively.
  • All patients had tumors in the final pathological report and were referred to other 2 cycles of chemotherapy with the same drugs.
  • The remaining 3 patients had disease progression, 2 of which died 6 and 12 months after surgery, respectively, and one patient missed the follow-up after salvage chemotherapy.
  • CONCLUSION: Retroperitoneal lymph node dissection for residual masses after chemotherapy is a high-morbidity procedure, even by experienced surgeons, although it remains an efficient modality of treatment in advanced germ cell carcinoma.
  • The high frequency of tumor found in the RPLFN following chemotherapy might have been caused by the small number of patients in this study.
  • [MeSH-major] Germinoma / drug therapy. Germinoma / pathology. Testicular Neoplasms / drug therapy. Testicular Neoplasms / pathology

  • Genetic Alliance. consumer health - Testicular cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15610570.001).
  • [ISSN] 1677-5538
  • [Journal-full-title] International braz j urol : official journal of the Brazilian Society of Urology
  • [ISO-abbreviation] Int Braz J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


3. Tomomasa H, Shimizu H, Sato S, Adachi Y, Ashizawa Y, Kamiyama Y, Okano Y, Sato M, Yoshii T, Iizumi T, Umeda T, Yazaki T: Clinical study of testicular germ cell tumors. Hinyokika Kiyo; 2001 Jun;47(6):389-95
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical study of testicular germ cell tumors.
  • A clinical statistical analysis on 65 patients with 68 testicular germ cell tumors was performed.
  • Thirty-six testes (53.7%) had seminomas and the remainder non-seminomatous germ cell testicular tumors (NSGCTTs).
  • Of the seminomas, 31 (88.6%) were in stage I and the others showed distant metastases at presentation.
  • Of the 32 NSGCTTs, 22 (68.8%) were in stage I.
  • Immunosuppressive acidic protein (IAP) was a useful diagnostic tumor marker as well as alpha-feto protein (AFP), beta-human chorionic gonadotropin (beta-hCG) and lactic dehydrogenase (LDH).
  • We adopted a surveillance policy in more than half of the stage I patients and obtained acceptable results.
  • In the remaining cases, therapies including combination chemotherapy, radiation and salvage operation were performed after orchiectomy.
  • The three-year survival rate was 98.0, 100.0 and 26.7%, for stage I, II and III patients respectively.
  • [MeSH-major] Germinoma. Testicular Neoplasms
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Combined Modality Therapy. Humans. Male. Middle Aged. Neoplasm Proteins / analysis. Neoplasm Staging. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11496394.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / immunosuppressive acidic protein
  •  go-up   go-down


Advertisement
4. Seseke S, Bierwirth S, Strauss A, Ringert RH, Seseke F: Long-term clinical outcome in patients with stage-I nonseminomatous germ cell cancer. A critical review of own treatment modalities in a retrospective study. Int Braz J Urol; 2008 Nov-Dec;34(6):715-22; discussion 723-4
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term clinical outcome in patients with stage-I nonseminomatous germ cell cancer. A critical review of own treatment modalities in a retrospective study.
  • PURPOSE: The optimal management of patients with clinical stage I non-seminomatous germ cell testicular cancer (NSGCT I) was considered controversial until the European Germ Cell Cancer Consensus Group determined unambiguous treatment strategies.
  • After orchiectomy, 39 patients were treated with chemotherapy, 7 patients underwent retroperitoneal lymph node dissection and 6 men were managed using a surveillance strategy.
  • Survival, recurrence rate and time of recurrence were evaluated.
  • The histological staging and treatment modality was related to the relapse.
  • RESULTS: Tumor specific overall mortality was 3.8%.
  • The mortality and relapse rate of the surveillance strategy, retroperitoneal lymph node dissection and chemotherapy was 16.7% / 50%, 14.3% / 14.3% and 0% / 2.5% respectively.
  • CONCLUSIONS: Following the European consensus on diagnosis and treatment of germ cell cancer in patients with NSGCT Stage I any treatment decision must be individually related to the patient according to prognostic factors and care capacity of the treating centre.
  • In case of doubt, adjuvant chemotherapy should be the treatment of choice, as it provides the lowest risk of relapse or tumor related death.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / surgery. Testicular Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Disease-Free Survival. Follow-Up Studies. Humans. Lymph Node Excision. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Orchiectomy. Retrospective Studies. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19111076.001).
  • [ISSN] 1677-6119
  • [Journal-full-title] International braz j urol : official journal of the Brazilian Society of Urology
  • [ISO-abbreviation] Int Braz J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


5. Custureri F, Urciuoli P, Iavarone C, D'Orazi V, Gabatel R, Ghinassi S, Patrizi G, Palazzini G, Di Matteo FM, Peparini N: Laparoscopic retroperitoneal lymphadenectomy for stage I non-seminomatous testicular tumors. Hepatogastroenterology; 2005 Nov-Dec;52(66):1677-80
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic retroperitoneal lymphadenectomy for stage I non-seminomatous testicular tumors.
  • Retroperitoneal lymph node dissection (RPLND) is the most accurate method to evaluate the presence and extent of retroperitoneal nodal metastases in clinical stage I non-seminomatous germ cell testicular carcinoma.
  • In our Department the open "nerve sparing" RPLND is already the standard surgical treatment for these tumors and laparoscopic technique is employed in surgical treatment of digestive diseases as cholelithiasis, hiatal hernias and gastrointestinal tumors; we report our first experience with laparoscopic RPLND in patients with low stage non-seminomatous germ cell testicular tumors (NSGCTT).
  • A laparoscopic modified template RPLND was performed in 5 high-risk patients with non-seminomatous germ cell clinical stage I tumors by a transperitoneal approach.
  • In one pathological stage II tumor a limited lymph node dissection was performed and the patient underwent postoperative chemotherapy.
  • Mean operative time was 190 minutes (range 160-210).
  • At mean follow-up of 16.3 months (range 12-21) the 4 operated patients with pathological stage I NSGCTT are disease free without ejaculatory or urinary dysfunction.
  • Our preliminary experience suggests that laparoscopic RPLND for stage I NSGCTT is feasible and safe for surgeons largely trained in either laparoscopic digestive surgery or open RPLND for whom the learning curve of that minimally invasive approach is lower than expected.
  • [MeSH-major] Germinoma / secondary. Germinoma / surgery. Laparoscopy / methods. Lymph Node Excision / methods. Testicular Neoplasms / pathology. Testicular Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Follow-Up Studies. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Neoplasm Staging. Predictive Value of Tests. Retroperitoneal Space. Risk Assessment. Sampling Studies. Survival Rate. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16334755.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


6. Kawai K, Kojima T, Miyanaga N, Hattori K, Hinotsu S, Shimazui T, Akaza H: Lectin-reactive alpha-fetoprotein as a marker for testicular tumor activity. Int J Urol; 2005 Mar;12(3):284-9
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lectin-reactive alpha-fetoprotein as a marker for testicular tumor activity.
  • In the present study, we used the subfraction profile of LCA-binding AFP to diagnose and monitor testicular tumor activity.
  • METHODS: Serum samples were collected from 21 testicular tumor patients, and the LCA-reactive fractions were determined by LCA-affinity electrophoresis coupled with antibody-affinity blotting.
  • The histological diagnosis was non-seminomatous germ cell tumor (NSGCT) in 15 patients and pure seminoma in six patients.
  • In testicular tumor patients, the broad band of AFP-L2 could not be completely separated from AFP-L3.
  • They included five patients who received chemotherapy, and three patients who underwent orchiectomy for stage I NSGCT.
  • CONCLUSION: Determination of LCA-reactive AFP might be a useful marker for testicular tumor activity in patients with lower AFP levels.
  • [MeSH-major] Germinoma / diagnosis. Seminoma / diagnosis. Testicular Neoplasms / diagnosis. alpha-Fetoproteins / analysis
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Feasibility Studies. Humans. Lectins / metabolism. Male. Neoplasm Staging. Orchiectomy. Protein Isoforms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15828957.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Lectins; 0 / Protein Isoforms; 0 / alpha-Fetoproteins
  •  go-up   go-down


7. Valdevenito Sepúlveda JP, Merhe Nieva E, Valdevenito Sepúlveda R, Cuevas Toro M, Gómez Gallo A, Bermúdez Luna H, Contreras Meléndez L, Gallegos Méndez I, Gallardo Escobar J, Palma Ceppi C: [Reduced retroperitoneal lymphadenectomy for clinical stage I non seminomatous germ cell testicular cancer]. Arch Esp Urol; 2007 Apr;60(3):245-54
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Reduced retroperitoneal lymphadenectomy for clinical stage I non seminomatous germ cell testicular cancer].
  • [Transliterated title] Linfadenectomia retroperitoneal reducida en cancer testicular de celulas germinales no seminomatoso estadio clinico I.
  • OBJECTIVES: The best treatment of clinical stage I non-seminomatous germ cell testicular cancer (NSGCTC) is controversial.
  • Lymphadenectomy allows an adequate retroperitoneal staging and cures up to 70% of patients in pathological stage II.
  • The objective of this study is to analyse our experience in the treatment of this patients with radical orchiectomy and reduced retroperitoneal lymphadenectomy (RRL) as the initial treatment.
  • METHODS: Retrospective study of patients with clinical stage I NSGCTC submitted to radical orchiectomy and RRL at the Urology Service of the University of Chile Clinical Hospital, from January 1990 to December 2000.
  • INCLUSION CRITERIA: retroperitoneal staging with computed tomography (CT), normal tumor markers after orchiectomy and testicular and retroperitoneal biopsy informed at our hospital.
  • The following metastatic risk factors in the testicular biopsy were checked: vascular invasion (venous and/or lymphatic), infiltration of tunica albuginea, rete testis, epididymis, and spermatic cord.
  • RESULTS: 36 patients with 37 testicular tumors were analysed (1 bilateral case).
  • Average surgery time 2 hr 7 min; average dissected lymph nodes 13.
  • Chemotherapy in 7 patients (19%) a total of 18 cycles.
  • Four cases of contralateral tumor during follow-up (11%).
  • Clinical stage I NSGCTC initially managed with RRL has a 100% survival.
  • [MeSH-major] Lymph Node Excision / methods. Neoplasms, Germ Cell and Embryonal / pathology. Neoplasms, Germ Cell and Embryonal / surgery. Testicular Neoplasms / pathology. Testicular Neoplasms / surgery

  • Genetic Alliance. consumer health - Testicular cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17601299.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


8. Stamatiou K, Papadopoulos P, Perlepes G, Galariotis N, Olympitis M, Moschouris H, Vasilakaki T: Mixed germ cell tumor of the testicle with ravdomuosarcomatous component: a case report. Cases J; 2009;2:9299

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed germ cell tumor of the testicle with ravdomuosarcomatous component: a case report.
  • INTRODUCTION: Testicular tumors can be classified as seminomatous and non-seminomatous germ-cell tumor (NSGCT) types.
  • Mixed germ cell tumors contain more than one germ cell component and are much more common than any of the pure histologic forms representing 32%-60% of all germ cell tumors.
  • Here we present a rare case of a mixed germ cell tumor composed of seminoma, Yolk sack tumor and teratoma containing a sarcoma component of somatic type malignancy.
  • The patient underwent right-sided high orchidectomy and was given chemotherapy of the BEP regimen.
  • After the 2nd cycle the patient discontinued the chemotherapy and when he came for follow-up after a gap of 3 months, despite the normalisation in tumor markers values, the retroperitoneal mass was relapsed.
  • CONCLUSION: More than 50% of germ-cell tumors include more than 2 basic germ-cell tumor types, with the exception of spermatocytic seminoma.
  • About 90% of the patients with nonseminomatous tumors can achieve complete cure with aggressive chemotherapy and most of them can be cured.
  • Although prognosis of testicular tumors depends largely on clinical stage, histological type and adhesion to the treatment influence the prognosis as well.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] APMIS. 2007 Nov;115(11):1296-301 [18092964.001]
  • [Cites] Yonsei Med J. 2006 Dec 31;47(6):887-91 [17191322.001]
  • [Cites] Mod Pathol. 2005 Feb;18 Suppl 2:S61-79 [15761467.001]
  • [Cites] Cancer Control. 2004 Nov-Dec;11(6):374-87 [15625525.001]
  • [Cites] Acta Cytol. 1995 Mar-Apr;39(2):249-51 [7887073.001]
  • [Cites] Cancer Res. 1994 Jan 15;54(2):362-4 [8275469.001]
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):257-73 [10680894.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1992;420(6):539-43 [1319095.001]
  • [Cites] Prog Clin Biol Res. 1985;203:1-34 [3008176.001]
  • [Cites] Cancer. 1990 Sep 15;66(6):1114-6 [1698114.001]
  • [Cites] J Urol. 1990 Jun;143(6):1232-4 [2188021.001]
  • [Cites] Bone Marrow Transplant. 2001 Oct;28(8):787-9 [11781632.001]
  • [Cites] IARC Sci Publ. 1993;(121):1-806 [8258476.001]
  • (PMID = 20062623.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2803963
  •  go-up   go-down


9. Maroto P, García del Muro X, Aparicio J, Paz-Ares L, Arranz JA, Guma J, Terrassa J, Barnadas J, Dorta J, Germà-Lluch JR: Multicentre risk-adapted management for stage I non-seminomatous germ cell tumours. Ann Oncol; 2005 Dec;16(12):1915-20
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentre risk-adapted management for stage I non-seminomatous germ cell tumours.
  • BACKGROUND: The Spanish Germ Cell Group is composed of 60 centres.
  • METHODS: From January 1994 to January 2004, 589 patients with stage I non-seminomatous germ cell tumours entered a risk-adapted surveillance protocol after orchiectomy.
  • Other patients (358/589; 61%) were kept on close follow-up (chest X-ray; serum tumour markers: first year every 2 months, second year every 3 months, third year every 4 months; abdominal computed tomography scans at every other outpatient control).
  • In the chemotherapy group, two patients relapsed at 12 and 14.5 months and they are presently free of disease.
  • Factors associated with relapse were embryonal carcinoma and vascular invasion in patients who refused chemotherapy.

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16126737.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide
  •  go-up   go-down


10. Mezvrishvili Z, Managadze L: Is bleomycin necessary in adjuvant chemotherapy of clinical stage I non-seminomatous testicular cancer? Georgian Med News; 2006 May;(134):25-8
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is bleomycin necessary in adjuvant chemotherapy of clinical stage I non-seminomatous testicular cancer?
  • The aim of our study was to assess the feasibility of bleomycin omission from two cycles of adjuvant bleomycin, etoposide and cysplatin (BEP) chemotherapy in patients with clinical stage I non-seminomatous germ cell tumors (NSGCT).
  • A total of 41 patients with high risk clinical stage I NSGCT of the testis were treated with adjuvant chemotherapy at our center from October 1994 to June 2005.
  • The criteria for high risk were lymphatic and/or vascular tumor invasion in the primary tumor.
  • 24 patients underwent adjuvant chemotherapy with two standard cycles of BEP (I group) and 17 patients received two alternative cycles of EP (II group).
  • Toxicity was analyzed on a per treatment cycle basis.
  • All the patients were alive and relapse-free at a median follow-up time of 75 and 49 months for groups 1 and 2 respectively.
  • In patients from group 1 more number of treatment cycles was associated with grade 2-3 leukopenia compared to group 2 (p=0,043).
  • The results of this study show that two cycles of EP regimen is as effective as two cycles of BEP chemotherapy in patients with clinical stage I NSGCT and may be suggested as a less toxic alternative approach to standard adjuvant treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / adverse effects. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Etoposide / therapeutic use. Humans. Male. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16783058.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Georgia (Republic)
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. Alexandre J, Fizazi K, Mahé C, Culine S, Droz JP, Théodore C, Terrier-Lacombe MJ: Stage I non-seminomatous germ-cell tumours of the testis: identification of a subgroup of patients with a very low risk of relapse. Eur J Cancer; 2001 Mar;37(5):576-82
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage I non-seminomatous germ-cell tumours of the testis: identification of a subgroup of patients with a very low risk of relapse.
  • There is no consensus about a reproducible prognostic model capable of distinguishing between clinical stage I non-seminomatous germ cell tumour (NSGCT) carrying a high and low risk of relapse.
  • The aim of this study was to assess the prognostic value of histological parameters in patients with stage I NSGCT undergoing surveillance after orchiectomy.
  • We retrospectively evaluated tumour specimens from 88 consecutive stage I NSGCT patients undergoing surveillance in our institution between 1984 and 1996.
  • This prognostic index, based on two standard pathological parameters, identified a subgroup with a very low risk of relapse that represents approximately one third of stage I patients.
  • Patients who belong to this subgroup should be managed by surveillance only, instead of retroperitoneal lymph node dissection (RPLND) or adjuvant chemotherapy.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / diagnosis. Teratoma / diagnosis. Testicular Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / blood. Disease-Free Survival. Follow-Up Studies. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Neoplasm Staging. Orchiectomy / methods. Prognosis. Prospective Studies. Retrospective Studies. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11290432.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


12. Lattouf JB, Mc Cormack M, Yelle L, Hadjeres R, Saad F: Recurrence of a non-seminomatous germ cell tumor in the seminal vesicle 20 years after initial diagnosis and treatment. Can J Urol; 2004 Aug;11(4):2350-1
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence of a non-seminomatous germ cell tumor in the seminal vesicle 20 years after initial diagnosis and treatment.
  • We present a case of a pathologic stage 1, right sided, non-seminomatous germ cell tumor recurrence in the left seminal vesicle, 20 years after initial diagnosis and treatment.
  • At 24 months of follow-up after completion of chemotherapy, digital rectal and TRUS examinations revealed complete resolution of the lesion.
  • We believe that this tumor is a late metastasis to the contralateral seminal vesicle.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Germinoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Bleomycin / administration & dosage. Cisplatin / administration & dosage. Etoposide / administration & dosage. Humans. Male. Middle Aged. Seminal Vesicles. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15380057.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


13. Porcaro AB, Zecchini Antoniolli S, Novella G, Martignoni G, Bassetto MA, Poli A, Schiavone D, Tallarigo C, D'Amico A, Ficarra V, Curti P: [Histopathologic risk factors in patients with non-seminomatous germ tumors of the testis in clinical stage 1. Retrospective study of 75 patients]. Arch Ital Urol Androl; 2001 Dec;73(4):177-80
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Histopathologic risk factors in patients with non-seminomatous germ tumors of the testis in clinical stage 1. Retrospective study of 75 patients].
  • [Transliterated title] Fattori istopatologici di rischio in pazienti con tumore germinale non seminomatoso del testicolo in stadio clinico 1. Uno studio retrospettivo su 75 pazienti.
  • OBJECTIVES: This retrospective study was performed to evaluate histopathologic prognostic risk factors in 75 patients on clinical stage 1 nonseminomatous germ cell cancer of the testis (NSGCTT).
  • METHODS: From September 1976 to February 2000 we operated on 75 patients for NSGCTT on clinical stage 1 disease.
  • After orchiectomy, therapeutic options included retroperitoneal lymph node dissection (RLND) for 44 patients (58.6%), surveillance for 26 (34.6%) and neoadjuvant chemotherapy for 5 (6.6%).
  • Testis primary tumor samples were assessed for studying prognostic risk factors that included vascular and/or lymphatic invasion (IV/IL+), percentage of embryonal carcinoma (%EC) and absence of yolk sac tumor (YS-).
  • CONCLUSIONS: EC% > 80 is a prognostic risk factor for disease relapse in patients with clinical stage 1 NSGCT who are selected in a high risk group requiring RPLND or neoadjuvant chemotherapy as therapeutical option.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11822063.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ITA
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


14. Thijssens K, Vaneerdeweg W, Schrijvers D, Eyskens E, Van Oosterom A: Retroperitoneal lymph node dissection as adjuvant therapy in the treatment of non-seminomatous testicular cancer. Acta Chir Belg; 2003 Nov-Dec;103(6):599-602
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal lymph node dissection as adjuvant therapy in the treatment of non-seminomatous testicular cancer.
  • OBJECTIVE: To assess the results of retroperitoneal lymph node dissection (RPLND) of residual masses in patients with disseminated non-seminomatous germ cell tumour treated with cisplatin-based chemotherapy, both in terms of extension of surgery, morbidity and survival.
  • PATIENTS AND METHODS: Retrospectively, all patients treated for non-seminomatous germ cell tumour at the University Hospital of Antwerp were studied from January 1987 till December 1997.
  • In patients with non-seminomatous testicular cancer more than stage I, the 'wait and see' strategy changed and patients were treated with chemotherapy.
  • Patients were assessed at the end of chemotherapy and if a residual masses persisted, a RPLND was performed.
  • RESULTS: Sixty patients had a non-seminomatous germ cell tumor of the testis and were analysed.
  • Thirteen patients with stage I disease were treated with orchiectomy only and none of these patients had recurrent disease.
  • Forty-seven patients were treated with cisplatin-based chemotherapy.
  • In two patients malignant cells or fibrotic tissue were found above the renal trunk and bilateral.
  • The survival of the patients treated with a RPLND was 97% and in the whole group of patients with a non-seminomatous testicular cancer 98%.
  • CONCLUSION: RPLND has a place in the treatment of patients with non-seminomatous testicular cancer after chemotherapy in case of residual masses.
  • [MeSH-major] Germinoma / secondary. Germinoma / surgery. Lymph Node Excision. Testicular Neoplasms / pathology. Testicular Neoplasms / surgery
  • [MeSH-minor] Adult. Belgium. Chemotherapy, Adjuvant. Cohort Studies. Disease-Free Survival. Follow-Up Studies. Humans. Lymph Nodes / pathology. Lymph Nodes / surgery. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Risk Assessment. Sensitivity and Specificity. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Testicular cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14743567.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


15. Wang JW, Yang L, Wang JY, Qu T, Cai RG, Huang J, Sun Y: [Long-term results of multimodality therapy of testicular germ cell tumor]. Zhonghua Zhong Liu Za Zhi; 2003 Jul;25(4):382-5
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term results of multimodality therapy of testicular germ cell tumor].
  • OBJECTIVE: To study the clinical characteristics, outcome, prognostic factors and survival of patients with testicular germ cell tumors (TGCTs).
  • METHODS: 107 TGCT patients received chemotherapy after orchiectomy.
  • 30.8% (33/107) patients had seminomas with 14 (42.4%) stage I lesions.
  • Seventy-four patients had non-seminomatous germ cell tumors (NSGCTT) with 21 (28.4%) stage I lesions.
  • Therapy including chemotherapy, radiation and necessary salvage operation were performed after orchiectomy.
  • RESULTS: Clinical stage and pathological type were the main prognostic factors.
  • Seventeen (26.6%) patients achieved CR by chemotherapy alone and an additional 8 patients (12.5%) achieved CR by chemotherapy plus salvage operation or radiation.
  • CONCLUSION: The long-term outcome for stage I germ cell tumors is excellent.
  • The treatment outcome and survival in patients with metastatic TGCTs can be greatly improved by adopting multi-modality therapy with combined chemotherapy as the chief means.
  • [MeSH-major] Germinoma / surgery. Orchiectomy. Seminoma / surgery. Testicular Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Child. Child, Preschool. Cisplatin / therapeutic use. Combined Modality Therapy. Etoposide / therapeutic use. Follow-Up Studies. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12921572.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; BEP protocol
  •  go-up   go-down


16. Maroto-Rey P, García Del Muro X, Paz-Ares L, Aparicio J, Sastre J, Dorca J, Terrassa J, Arranz JA, Barnadas J, Germa JR: Risk adapted surveillance for stage I non-seminomatous testicular tumors (NSGCT). Results of a prospective multicenter study. J Clin Oncol; 2004 Jul 15;22(14_suppl):4524

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk adapted surveillance for stage I non-seminomatous testicular tumors (NSGCT). Results of a prospective multicenter study.
  • : 4524 Background: Management of stage I NSGCT is controversial.
  • Our challenge in the Spanish Germ Cell Group composed of 60 hospitals was to reduce morbidity through a risk adapted surveillance protocol useful regardless of size of Hospital or geographical differences.
  • METHODS: From I/94 to II/2003, 593 patients with stage I NSGCT entered a risk-adapted surveillance protocol.
  • 360/593, 60.7% were in close follow-up (chest X ray and serum tumor markers every 2 m first year, every 3 m second year, every 4 m the third; abdominal Ct scan every other outpatient visit).
  • Chemotherapy consisted until 1999 of 3 cycles of Spanish BEP (Bleomicin 30 U/wk, Etoposide 100 mg/m<sup>2</sup>x4, Cisplatinum 25 mg/m<sup>2</sup>x4), later of 2 cycles and 21 patients received only one cycle.
  • Chemotherapy: No cancer specific mortality.
  • Relapses under surveillance: [Figure: see text] Only factor associated to relapse was Embrionary Carcinoma as the main component of histology.Eight patients presented a second testicular tumor on follow-up.
  • Patients who received chemotherapy may simplify their follow-up.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016021.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Lallave Martín F, Lomas Garrido M, Laguna Alvarez E, Asuar Aydillo S, Murillo Mirat J, Ramírez Zambrana A, Molina Suarez JL: [Testicular germ cell tumours: descriptive study of 13 years of experience in the health care area of Badajoz]. Arch Esp Urol; 2007 Jun;60(5):531-7
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Testicular germ cell tumours: descriptive study of 13 years of experience in the health care area of Badajoz].
  • OBJECTIVES: To describe the incidence of germ cell testicular tumors in our Center, their characteristics and therapy results.
  • METHODS: Retrospective study of 66 cases of germ cell testicular tumors diagnosed in the Health Area of Badajoz between 1993 and 2005.
  • RESULTS: Mean age of the time of diagnosis was 32 years (range 16-80 years), presenting a younger age patients with non seminomatous germ cell tumors (NSGCT) (mean age 30 years).
  • 86.5% of the patients did not have risk factors associated with the diagnosis of germ cell testicular tumor.
  • Testicular mass was the most frequent symptom, and a higher proportion of tumors were located in the left testicle (51.5%).
  • Non seminomatous germ cell tumors were the most frequent histological type (64.8%).
  • Stage I (72%) was the most frequent stage in the group of seminomatous tumors, in comparison with 68.5% of non seminomatous tumors.
  • Stages II-III appeared in 34.4% of the NSGCT and 28% of seminomatous, having worse prognosis.
  • 92% of the patients received adjuvant treatment with chemotherapy and/or radiotherapy, and curative surgery was the only treatment in the remainder 8%.
  • CONCLUSIONS: An increased incidence of germ cell testicular tumors have been verified over last years, mainly NSGCT Nevertheless, the diagnosis of advanced stages of the disease has diminished in favour of initial stages, which have a better prognosis for the patient.
  • Oncologycal treatment protocols have high cure rates, although a long-term follow-up is needed due to the natural history of these tumors.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal. Testicular Neoplasms
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Catchment Area (Health). Humans. Male. Middle Aged. Retrospective Studies. Spain. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17718207.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


18. Fernández-Ortega A, García del Muro X, Navarro M, Germà Lluch JR: [Adjuvant chemotherapy of non-seminoma stage I germ cell tumors of the testis]. Arch Esp Urol; 2000 Jul-Aug;53(6):487-90
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adjuvant chemotherapy of non-seminoma stage I germ cell tumors of the testis].
  • [Transliterated title] Tratamiento con quimioterapia adyuvante en los tumores germinales no seminoma de testículo estadio I.
  • OBJECTIVE: To review the treatment of stage I nonseminomatous germ cell testicular tumor with adjuvant chemotherapy.
  • RESULTS/CONCLUSIONS: Overall, 30% of stage I nonseminomatous germ cell testicular tumors that are followed recur within two subsequent years.
  • The most important are the presence of venous or lymphatic infiltration, the presence of a carcinoembryonic component and the absence of tumor of the endodermal sinus.
  • Over the last few years, some experience using two cycles of BEP adjuvant chemotherapy in patients at a higher risk have shown that this recurrence rate can be reduced to less than 5% with minimal late toxicity.
  • [MeSH-major] Germinoma / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Follow-Up Studies. Humans. Lymph Node Excision. Male. Neoplasm Staging. Risk Factors

  • Genetic Alliance. consumer health - Seminoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11002516.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] SPAIN
  • [Number-of-references] 14
  •  go-up   go-down


19. Langenkamp S, Albers P: [Testicular cancer--is there an indication for adjuvant or neoadjuvant systemic therapy?]. Urologe A; 2007 Oct;46(10):1389-90, 1392-4
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Testicular cancer--is there an indication for adjuvant or neoadjuvant systemic therapy?].
  • Testicular cancer represents between 1 and 1.5% of male neoplasms and 5% of all urological tumours.
  • There are indications for adjuvant or neoadjuvant systemic therapy in all stages of seminomatous and non-seminomatous testicular cancer.
  • The treatment decision is strongly stage dependent.
  • The primary treatment of choice for advanced disease is chemotherapy.
  • In earlier stages a risk-adapted treatment should be used and besides chemotherapy, surveillance, radiotherapy and sometimes retroperitoneal lymph node dissection can be considered.
  • In early stages it is important to reduce immediate adjuvant treatment in as many patients as possible to avoid acute and late toxicities.
  • In advanced stages randomized trials have to clarify if there could be a better outcome with adding new agents or with high-dose chemotherapy for patients with "poor prognosis" and adverse features or patients with a chemoresistant relapse.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neoadjuvant Therapy. Neoplasms, Germ Cell and Embryonal / drug therapy. Neoplasms, Germ Cell and Embryonal / radiotherapy. Testicular Neoplasms / drug therapy. Testicular Neoplasms / radiotherapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Bleomycin / administration & dosage. Bleomycin / adverse effects. Carboplatin / administration & dosage. Carboplatin / adverse effects. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Disease-Free Survival. Etoposide / administration & dosage. Etoposide / adverse effects. Humans. Lymph Node Excision. Male. Neoplasm Invasiveness. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Orchiectomy. Prognosis. Radiotherapy, Adjuvant. Randomized Controlled Trials as Topic

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2005 Jul 23-29;366(9482):293-300 [16039331.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):692-701 [9469359.001]
  • [Cites] J Urol. 1996 Feb;155(2):587-9 [8558665.001]
  • [Cites] Urology. 2004 Mar;63(3):556-61 [15028457.001]
  • [Cites] Actas Urol Esp. 1997 Nov-Dec;21(10):961-3 [9494159.001]
  • [Cites] J Urol. 1997 May;157(5):1705-9; discussion 1709-10 [9112510.001]
  • [Cites] J Urol. 1994 Aug;152(2 Pt 1):424-7 [8015086.001]
  • [Cites] J Urol. 1999 Feb;161(2):472-5; discussion 475-6 [9915429.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8717-23 [16260698.001]
  • [Cites] Ann Oncol. 2003 Jun;14(6):867-72 [12796024.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1505-12 [12697874.001]
  • [Cites] J Clin Oncol. 2007 Jan 20;25(3):247-56 [17235042.001]
  • [Cites] Eur Urol. 1997;31(4):405-7 [9187898.001]
  • [Cites] Cancer. 1990 Mar 1;65(5):1115-8 [2302662.001]
  • [Cites] J Cancer Res Clin Oncol. 1996;122(1):63-6 [8543595.001]
  • [Cites] Eur J Cancer. 1995 Sep;31A(10):1599-604 [7488408.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3450-6 [10550141.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1146 [10561173.001]
  • [Cites] Br J Urol. 1993 Mar;71(3):326-35 [8386580.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2546-52 [9215823.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1629-40 [11250991.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1287-93 [9552027.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1200-8 [15718317.001]
  • [Cites] J Clin Oncol. 1992 Nov;10(11):1762-8 [1403057.001]
  • [Cites] Ann Oncol. 2003 Jan;14 (1):91-6 [12488299.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1101-6 [12637477.001]
  • [Cites] Ann Oncol. 2004 Sep;15(9):1377-99 [15319245.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):290-4 [9440755.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2553-8 [9215824.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4092-9 [14559885.001]
  • [Cites] J Urol. 1992 Nov;148(5):1453-5; discussion 1455-6 [1279211.001]
  • (PMID = 17874229.001).
  • [ISSN] 0340-2592
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; BEP protocol
  •  go-up   go-down


20. Houlgatte A, Dourthe LM, Bernard O: [Update on about testicular cancer]. Bull Cancer; 2002 Jan;89(1):47-56
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Update on about testicular cancer].
  • The last two years publications are mainly concerning the following themes: the detection of testicular tumor for high risk patients.
  • The treatment of stage one non seminomatous germ cell tumors is also detailed with reference to the three therapeutic options.
  • The surgical treatment is evoked through laparoscopic surgery, surgery of residual masses and salvage surgery.
  • Recent acquisitions in chemotherapy matters allow a simplification of protocols.
  • The salvage chemotherapy is evaluated and its results are assessed.
  • The innovations in imaging are essentially focused on position emission tomography in the evaluation of these tumours but also on magnetic resonance imaging.
  • [MeSH-major] Germinoma / therapy. Lymph Node Excision / methods. Testicular Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Magnetic Resonance Imaging. Male. Neoplasm, Residual. Risk Factors. Tomography, Emission-Computed

  • Genetic Alliance. consumer health - Testicular cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11847026.001).
  • [ISSN] 0007-4551
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 38
  •  go-up   go-down


21. Cheung WY, Demers A, Hossain D, Owen T, Ahmed S, Czaykowski PM: Appropriateness of testicular cancer management: a population-based cohort study. Can J Urol; 2007 Jun;14(3):3542-50
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Appropriateness of testicular cancer management: a population-based cohort study.
  • OBJECTIVE: Testicular cancer is a highly curable malignancy of young men.
  • A 3-year population-based review of testicular cancer patients in Manitoba, Canada was undertaken to evaluate our management patterns.
  • METHODS: Men diagnosed with testicular cancer from 1998 to 2000 were identified from the Provincial Cancer Registry.
  • RESULTS: Seventy-eight men were identified with 80 testicular cancers: 46 (59%) patients had 48 seminomas and 32 (41%) had non-seminomatous germ cell tumors (NSGCT).
  • One or more pre-operative tumor markers were missing or unavailable in 41 (52%) cases.
  • Median time from scrotal ultrasound to orchiectomy was 7 days, but was greater than 2 weeks in 13 (16%) patients.
  • Post-orchiectomy management of both seminoma and NSGCT patients was largely within acceptable limits apart from some non-standard chemotherapy choices in advanced stage disease, and significant departures from standard recommendations regarding surveillance.
  • CONCLUSIONS: Although clinical outcomes do not appear to have been compromised, deficiencies are evident in testicular cancer management in Manitoba from 1998 to 2000, indicating the need for well-defined management guidelines and improved education of caregivers.
  • [MeSH-major] Testicular Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / analysis. Combined Modality Therapy. Humans. Male. Manitoba / epidemiology. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Orchiectomy. Population Surveillance. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Testicular cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17594744.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


22. Durand X, Vedrine L, Deligne E, Desfemmes FR, Ceccaldi B, Houlgatte A: [Management of testicular seminoma with elevation of alpha fetoprotein. A case report]. Prog Urol; 2008 Mar;18(3):190-2
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Management of testicular seminoma with elevation of alpha fetoprotein. A case report].
  • The authors report a case of stage N3 pure testicular seminoma associated with paradoxical elevation of alphafoetoprotein (AFP).
  • Despite the absence of histological arguments after review of the slides, this lesion was considered to be a stage pT1 N3 M0 S3 non seminomatous germ cell tumour with a poor prognosis.
  • Laboratory and then clinical relapse at three months was treated by salvage chemotherapy followed by retroperitoneal lymph node dissection.
  • [MeSH-major] Seminoma / pathology. Testicular Neoplasms / pathology. alpha-Fetoproteins / analysis
  • [MeSH-minor] Adult. Antineoplastic Agents. Biomarkers, Tumor / blood. Humans. Lymph Node Excision. Male

  • Genetic Alliance. consumer health - Seminoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18472076.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / alpha-Fetoproteins
  •  go-up   go-down


23. Leisinger HJ, Donohue JP: The role of retroperitoneal surgery in testis cancer. Crit Rev Oncol Hematol; 2002 Oct;44(1):71-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There is an increasing interest in surveillance rather than in primary retroperitoneal lymph node dissection (RPLND) for stage I non-seminomatous germ cell tumors (NSGCT).
  • Adjuvant chemotherapy has become an efficient treatment option for high risk non-seminomatous germ cell testis cancer, however, biological and histologic risk factors of the primary tumor are not yet precisely defined.
  • To determine the appropriate management of patients with testicular cancer, postoperative morbidity after RPLND and risk of chemotherapy-induced morbidity must be balanced.
  • As treatment morbidity and its intensity have a major impact on testis cancer patient quality of life, the choice of management must be based on the patient's social situation, his personal needs, and the doctor's experience and resources.
  • [MeSH-major] Lymph Node Excision. Testicular Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Antineoplastic Agents / toxicity. Humans. Male. Neoplasms, Germ Cell and Embryonal / therapy. Retroperitoneal Space / surgery. Seminoma / pathology. Seminoma / surgery. Seminoma / therapy

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12399000.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 74
  •  go-up   go-down


24. Amato RJ, Ro JY, Ayala AG, Swanson DA: Risk-adapted treatment for patients with clinical stage I nonseminomatous germ cell tumor of the testis. Urology; 2004 Jan;63(1):144-8; discussion 148-9
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk-adapted treatment for patients with clinical stage I nonseminomatous germ cell tumor of the testis.
  • OBJECTIVES: To evaluate whether two courses of chemotherapy after orchiectomy in patients with clinical Stage I nonseminomatous germ cell testicular tumor at high risk of relapse will spare patients additional chemotherapy or surgery.
  • METHODS: High-risk patients had one or more of the following: preorchiectomy alpha-fetoprotein level of 80 ng/dL or greater, 80% embryonal cell carcinoma or greater, or vessel invasion in the primary tumor.
  • High-risk patients were offered two 21-day courses of outpatient chemotherapy consisting of carboplatin, etoposide, and bleomycin.
  • Low-risk patients and high-risk patients not receiving chemotherapy were observed.
  • All but eight of the high-risk patients received chemotherapy.
  • No patient who underwent chemotherapy developed relapse, although 1 patient with normal biomarkers and a late-appearing mass underwent retroperitoneal lymphadenectomy for mature teratoma.
  • Two of the 23 low-risk patients had disease relapse; both successfully underwent chemotherapy.
  • The nonhematologic toxicity was mild in patients receiving chemotherapy, and no patient required hospitalization.
  • CONCLUSIONS: Two courses of postorchiectomy adjuvant chemotherapy were safe and well tolerated and markedly decreased the relapse rate in high-risk patients with clinical Stage I nonseminomatous germ cell testicular tumor without additional surgery or more protracted chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Germinoma / drug therapy. Orchiectomy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Biomarkers, Tumor / blood. Bleomycin / administration & dosage. Carboplatin / administration & dosage. Carcinoma, Embryonal / drug therapy. Carcinoma, Embryonal / pathology. Carcinoma, Embryonal / surgery. Combined Modality Therapy. Disease-Free Survival. Drug Administration Schedule. Etoposide / administration & dosage. Humans. Lymph Node Excision. Male. Neoplasm Invasiveness. Neoplasm Proteins / analysis. Neoplasm Staging. Neoplasms, Multiple Primary / drug therapy. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / surgery. Neoplasms, Second Primary / drug therapy. Neoplasms, Second Primary / pathology. Neoplasms, Second Primary / surgery. Prognosis. Risk Factors. Seminoma / drug therapy. Seminoma / pathology. Seminoma / surgery. Teratoma / drug therapy. Teratoma / pathology. Teratoma / surgery. Treatment Outcome. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Nonseminomatous germ cell tumor.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14751368.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / alpha-Fetoproteins; 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


25. Bhayani SB, Ong A, Oh WK, Kantoff PW, Kavoussi LR: Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular cancer: a long-term update. Urology; 2003 Aug;62(2):324-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular cancer: a long-term update.
  • OBJECTIVES: To assess retrospectively the long-term cancer control in patients undergoing laparoscopic retroperitoneal lymph node dissection (RPLND) in the management of clinical Stage I nonseminomatous germ cell testicular tumors.
  • All patients had clinical Stage I nonseminomatous germ cell testicular tumor, with vascular invasion and/or embryonal carcinoma in the orchiectomy specimen.
  • Patients with retroperitoneal metastases were offered two cycles of chemotherapy.
  • Two patients had recurrence, one in the chest, and one biochemically, and both were free of disease after chemotherapy.
  • Twelve of 29 patients had lymph nodes with metastatic testicular cancer.
  • Ten of these patients underwent adjuvant chemotherapy and were free of disease with 6.3 years of follow-up.
  • One patient had a biochemical recurrence after positive RPLND and was salvaged with chemotherapy.
  • CONCLUSIONS: Laparoscopic RPLND is a safe, minimally invasive treatment option in patients with clinical Stage I nonseminomatous germ cell testicular tumor.
  • The cancer control appears to be similar, with minimal morbidity compared with the open procedure.
  • [MeSH-major] Germinoma / surgery. Laparoscopy / methods. Lymph Node Excision / methods. Retroperitoneal Space / surgery. Seminoma / surgery. Testicular Neoplasms / surgery
  • [MeSH-minor] Adult. Follow-Up Studies. Humans. Male. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12893344.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


26. Mezvrishvili Z, Managadze L: Complications of nerve sparing retroperitoneal lymph node dissection. Georgian Med News; 2006 Mar;(132):20-3
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nerve sparing retroperitoneal lymph node dissection is standard treatment method for early stage non-seminomatous germ cell tumor.
  • However, an alternative approaches (surveillance policy, adjuvant and primary chemotherapy) have approximately the same capability for cure.
  • We assessed associated complications of nerve sparing retroperitoneal lymph node dissection in 33 patients (25 with clinical stage I and 8 with clinical stage IIA) treated at our center from June 1996 to November 2005.
  • Postoperatively 19 out of 33 patients were classified as pathological stage I and 14 as pathological stage IIA.
  • The data indicate that nerve sparing RPLND is a well tolerated urologic procedure with a low early and no late morbidity.
  • [MeSH-major] Germinoma / surgery. Lymph Node Excision / methods. Peripheral Nerves / physiology. Postoperative Complications. Salvage Therapy / methods. Testicular Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16636371.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Georgia (Republic)
  •  go-up   go-down






Advertisement